̽»¨Ö±²¥

A major new drive to understand, diagnose and treat Alzheimer’s disease has begun in Cambridge.

̽»¨Ö±²¥path from innovation to impact can be long and complex. Here we describe the 30-year journey behind the development of a drug now being used to treat multiple sclerosis.

̽»¨Ö±²¥Cambridge Research Institute (CRI) is driving the development of new approaches for the early detection, prevention and treatment of cancer.

Cancer Research UK is the world's leading independent charity dedicated to cancer research, spending around £300 million a year on world-class research to beat cancer. In November 2008, the charity launched a five-year plan to focus research on core areas of science that will have the greatest impact on reducing cancer deaths, with an emphasis on cancers that have poor survival rates.

Two new regions of the human genome linked to breast cancer have been found by an international team of scientists led by Cambridge ̽»¨Ö±²¥ researchers; one increases the risk while the other reduces the risk of developing breast cancer.

̽»¨Ö±²¥strength of Cambridge as a globally-competitive centre for biomedical research, clinical education and healthcare innovation was confirmed today by the UK’s Department of Health.

Scientists from Cambridge ̽»¨Ö±²¥ have discovered four rare mutations of a gene associated with type 1 diabetes (T1D) that reduce the risk of developing the disease. Their findings, published today in the journal Science, suggest a link between T1D and the enterovirus (a common virus that enters via the gastrointestinal tract but is often non-symptomatic).

Epigenetics is taking the biomedical research world by storm; three Cambridge scientists use examples from their own research to explain why.

Cambridge neurologists have shown that an antibody used to treat leukaemia also limits and repairs the damage in multiple sclerosis.

GlaxoSmithKline (GSK) has signed its first agreement with the ̽»¨Ö±²¥ to optimise the early clinical development of new GSK medicines for obesity and addictive disorders.